A randomized control trial of prophylactic application of recombinant human thrombopoietin (rhTPO) for thrombocytopenia caused by high-dosed chemotherapy

INTERVENTION: CONDITION: Thrombocytopenia caused by high‐dosed chemotherapy PRIMARY OUTCOME: Platelets infusion amount and rate; SECONDARY OUTCOME: Extreme value of count of platelets and it's change;Rate of hemorrhage activity;Mean of count of platelet at different time point;Thrombocytopoiesis rate and duration; INCLUSION CRITERIA: 1. In‐patiants with malignant solid tumor proved by histopathology or Cytology; 2. general state of health is good. ECOG Performance Status <=2 and Expectant survival 3 >months; 3. Male and female aged 18 to 70 years old; 4. Chemotherapy interval >=4 weeks from the last radiation therapy or isotope treatment; count of blood cell before treatment should in following range: WBC 4.0*10^9/L to 10*10^9/L, Hb 95g/L to 165g/L, PlT 75*10^9/L to 300*10^9/L; 5. Liver and kidney function are normal; Electrocardiogram is normal; 6. Patients will receive 2 periods equally high‐dosed chemotherapy; 7. Patients with good compliance and accepting follow‐up; 8. Inform of consents were signed voluntarily.